Dermata Therapeutics Changes Independent Auditor, Appointing Former Firm CBIZ CPAs

summarizeSummary

Dermata Therapeutics, Inc. announced the dismissal of Baker Tilly US, LLP as its independent auditor and the appointment of CBIZ CPAs P.C., which previously served the company, with no reported disagreements.

check_boxKey Events

• Auditor Dismissal

  Dermata Therapeutics dismissed Baker Tilly US, LLP as its independent registered public accounting firm, effective January 31, 2026.

• No Disagreements Reported

  The company stated there were no disagreements on accounting principles or reportable events with Baker Tilly, though prior audit reports included a going concern explanatory paragraph.

• New Auditor Appointment

  CBIZ CPAs P.C. was appointed as the new independent auditor, effective February 2, 2026.

• Return to Former Auditor

  CBIZ CPAs previously served as the company's auditor from 2016 to 2023.

auto_awesomeAnalysis

This 8-K filing details a change in Dermata Therapeutics' independent registered public accounting firm. While the dismissal of an auditor can often be a red flag, the company explicitly stated that there were no disagreements on accounting principles or reportable events with the outgoing firm, Baker Tilly. It is notable that Baker Tilly's previous audit reports included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern, a pre-existing concern for investors. The appointment of CBIZ CPAs P.C., a firm that previously audited the company, could suggest a move towards a familiar and established relationship. For a micro-cap company like Dermata Therapeutics, maintaining stable and credible financial oversight is crucial, especially given its ongoing financial challenges. Investors will monitor future financial statements for any new disclosures or changes in audit opinions.